Genelux Corp. (GNLX)
NASDAQ:GNLX
Top Page
Genelux Corp.
(NASDAQ:GNLX)
Select Model
Select Model
Rating:44Neutral
Price Target:
$2.50
▼(-5.30% Downside)
Action:ReiteratedDate:03/20/26
The score is primarily weighed down by very weak financial performance (large ongoing losses, heavy cash burn, and a shrinking equity base). Technicals also signal a downtrend with negative momentum. Corporate events add modest support via clinical updates and financing flexibility, but the equity-raise/ATM structures elevate dilution risk, and valuation is difficult to assess meaningfully given negative earnings.
Positive Factors
Proprietary oncolytic platform
Genelux’s proprietary oncolytic vaccinia virus platform and two lead clinical candidates (GEN-1, GEN-2) provide a durable R&D engine. A differentiated platform can generate multiple assets, support partnerships, and create long-term upside tied to clinical progress rather than one-off products.
Negative Factors
High cash burn
Sustained negative operating and free cash flow at roughly -$20M to -$26M annually implies the company must repeatedly access capital to fund operations. Over a multi-month horizon this materially raises financing and dilution risk and constrains strategic choices.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary oncolytic platform
Genelux’s proprietary oncolytic vaccinia virus platform and two lead clinical candidates (GEN-1, GEN-2) provide a durable R&D engine. A differentiated platform can generate multiple assets, support partnerships, and create long-term upside tied to clinical progress rather than one-off products.
Read all positive factors
Genelux Corp. (GNLX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$113.36M
Dividend YieldN/A
Average Volume (3M)156.94K
Price to Earnings (P/E)―
Beta (1Y)0.73
Revenue Growth-100.00%
EPS Growth7.80%
CountryUS
Employees24
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.24
Shares Outstanding44,805,813
10 Day Avg. Volume178,540
30 Day Avg. Volume156,945
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)14.04
Price to Sales (P/S)20261.21
P/FCF Ratio-6.15
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue11.96K
Enterprise Value/Gross Profit-338.02
Enterprise Value/Ebitda-2.93
Forecast
1Y Price Target
$21.00Price Target Upside695.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.82
Revenue Forecast (FY)N/A
Genelux Corp. Business Overview & Revenue Model
Company Description
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate i...
How the Company Makes Money
Genelux is a clinical-stage company and does not have publicly disclosed, recurring product revenue from approved therapies. As a result, its operations are primarily funded through external financing rather than sales. null...
Genelux Corp. Financial Statement Overview
Summary
Income Statement
10
Very Negative
Balance Sheet
45
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.00K | 8.00K | 170.00K | 11.07M | 0.00 |
| Gross Profit | -566.00K | -895.00K | -848.00K | 10.10M | -895.00K |
| EBITDA | -32.64M | -28.97M | -26.46M | -1.73M | -13.67M |
| Net Income | -32.15M | -29.87M | -28.30M | -5.21M | -17.80M |
Balance Sheet | |||||
| Total Assets | 19.03M | 34.72M | 27.89M | 5.53M | 8.13M |
| Cash, Cash Equivalents and Short-Term Investments | 14.60M | 30.89M | 23.19M | 397.00K | 4.50M |
| Total Debt | 1.69M | 1.87M | 2.52M | 26.35M | 25.31M |
| Total Liabilities | 7.48M | 8.44M | 8.42M | 41.31M | 41.24M |
| Stockholders Equity | 11.54M | 26.27M | 19.47M | -35.78M | -33.11M |
Cash Flow | |||||
| Free Cash Flow | -26.37M | -21.61M | -21.30M | -3.62M | -6.58M |
| Operating Cash Flow | -25.27M | -21.23M | -20.27M | -3.57M | -6.58M |
| Investing Cash Flow | 12.14M | -8.13M | -14.72M | -49.00K | 0.00 |
| Financing Cash Flow | 9.89M | 28.51M | 44.02M | -478.00K | -270.00K |
Genelux Corp. Technical Analysis
Positive
2.64
Price Trends
2.62
Positive
3.28
Negative
3.84
Negative
Market Momentum
-0.02
Negative
51.67
Neutral
46.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GNLX, the sentiment is Positive. The current price of 2.64 is above the 20-day moving average (MA) of 2.55, above the 50-day MA of 2.62, and below the 200-day MA of 3.84, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 51.67 is Neutral, neither overbought nor oversold. The STOCH value of 46.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GNLX.
Genelux Corp. Risk Analysis
Genelux Corp. disclosed 86 risk factors in its most recent earnings report. Genelux Corp. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Genelux Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $180.56M | -1.38 | -65.76% | ― | ― | -17.43% | |
52 Neutral | $256.31M | -1.00 | 789.35% | ― | -72.54% | -19972.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $152.31M | -0.86 | -55.02% | ― | -46.92% | 20.26% | |
48 Neutral | $424.90M | -40.48 | -110.72% | ― | ― | 77.08% | |
44 Neutral | $113.36M | -5.04 | -98.72% | ― | -100.00% | 7.80% | |
44 Neutral | $174.00M | -0.71 | -60.15% | ― | -8.79% | 81.36% |
* Healthcare Sector Average
GNLX
Genelux Corp.
2.64
0.18
7.32%
CHRS
Coherus Biosciences
1.80
0.74
69.81%
FATE
Fate Therapeutics
1.34
0.22
19.64%
TNXP
Tonix Pharma
13.35
-3.65
-21.47%
CRBP
Corbus Pharmaceuticals
10.02
4.03
67.28%
FBRX
Forte Biosciences
32.42
26.58
455.14%
Genelux Corp. Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Genelux Establishes $100 Million At-The-Market Equity Program
Positive
Mar 19, 2026
On March 19, 2026, Genelux Corporation entered into a Sales Agreement with TD Securities (USA) LLC, allowing the company to offer and sell up to $100 million of its common stock from time to time through at-the-market offerings and other negotiate...
Business Operations and StrategyRegulatory Filings and Compliance
Genelux Updates Corporate Presentation for Investors and Stakeholders
Neutral
Feb 2, 2026
On February 2, 2026, Genelux Corporation updated its corporate presentation to reflect new business and strategic information. The refreshed materials, which management may use in future investor and stakeholder meetings, have been made available ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.